PPT-Immunotherapy for advanced cervical cancer

Megan Swanson MD MPH Assistant Professor Gynecologic Oncology UCSF Limited effective treatment options for advanced cervical cancer Problem when cervical cancer is advanced andor recurrent . Interactions and Interventions. Jean R. Anderson, M.D.. Jhpiego, an affiliate of Johns Hopkins University. The Johns Hopkins University School of Medicine. Cervical Cancer. Latest data on cervical cancer incidence and mortality (GLOBOCAN 2008, IARC*):. Based on the 2012 Recommendations (ASCCP). Sarah Lamanuzzi, MD, FAAFP. Disclosures. I have no disclosures other than: the ASCCP gave permission for use of their slide content.. The American Society for Colposcopy and Cervical Pathology. “Cervical Cancer Screening Recommendations, . Hazel Lewis. Public Health Physician. Wellington. Cartwright Forum, 7 August 2015. NCSP. -. R. centralised. 1965. 1990. 2000. 1988. Cartwright Report. NCSP . established . In 14 AHB. 1996. NSU. Gisborne Inquiry (CSI). The Obstetrics & Gynecological Society of Bhopal. &. AMPOGS Research Public Welfare Society. BREAST . AND GENITAL TRACT CANCER INCIDENCE RATES PER 100,000 . FEMALES worldwide. 31.3. 17.4. 8.3. The Future of Cancer Care. Brad . Loncar. Biotech . commentator . and . investor for 8+ . years.. Manager of a biotech-focused family office.. Franklin Templeton Investments and U.S. Department of the Treasury.. By. Dr. . Aida Ahmed . Fadlala. Dr. Dina Sami Khalifa. Geneva Foundation for Medical Education and Research . GFMER Sudan 2012. Forum No: ( 2 ). Name of presenter. Name. Position. Institution. Aida Ahmed . What is cervical cancer?. The cervix, lower part of the uterus. Abnormal cells. Triggered by a type virus. Anatomy of the cervix. Causes of cervical cancer. The human . papillomavirus. (HPV) . Chronic infections. Cervical Cancer Statistics. United . States. An estimated 12,000 new cases each year. An estimated 4,000 . deaths . each year . 700,000 cases of severe . pre-cancer . International. Approximately 500,000 cases expected worldwide each year!. Presented by:. The Foundation for Women’s . Cancer. © . Updated September 2012. About this . presentation. This presentation is intended to help women take an active role in their health care. It does not replace the judgment of a health care professional in diagnosing and treating disease.. Associate Professor Philip Beale. Chair ANZGOG Clinical Trials Group. Medical Oncologist Sydney. Concord Hospital. Chris O’Brien Lifehouse. Royal Prince Alfred Hospital. Outline. Background to immunotherapy. (Food Desensitization). Yale University ECHO Series. Session 5. Stephanie Leeds, MD FAAAAI. Disclosure. The following individuals have no conflicts of interest to disclose relevant to this activity:. Peanut Allergy. Immunotherapy Options. Oral Immunotherapy. Patient/Disease Characteristics and Response to AR101. Patient/Disease Characteristics and Response to AR101: Subgroup Analysis. Patient/Disease Characteristics and Response to AR101: Discussion. IOTN THE IMMUNO-ONCOLOGY TRANSLATIONAL NETWORK Advancing Research Progress to Improve Immunotherapy and Immunoprevention Blue Ribbon Panel’s Recommendation: Create A Translational Science Netw Success At Last!. Russell M. Eldridge MD. What is Immunotherapy, and why is everyone talking about it?. An old idea finally delivers the biggest breakthrough in cancer treatment in the last 30 years.